Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Income: 2016-2024

Historic Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$265.5 million.

  • Rhythm Pharmaceuticals' Operating Income fell 19.98% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 29.87%. This contributed to the annual value of -$265.5 million for FY2024, which is 44.02% down from last year.
  • According to the latest figures from FY2024, Rhythm Pharmaceuticals' Operating Income is -$265.5 million, which was down 44.02% from -$184.4 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Operating Income's 5-year high stood at -$170.1 million during FY2021, with a 5-year trough of -$265.5 million in FY2024.
  • Its 3-year average for Operating Income is -$209.7 million, with a median of -$184.4 million in 2023.
  • Data for Rhythm Pharmaceuticals' Operating Income shows a maximum YoY plummeted of 44.02% (in 2024) over the last 5 years.
  • Over the past 4 years, Rhythm Pharmaceuticals' Operating Income (Yearly) stood at -$170.1 million in 2021, then decreased by 5.35% to -$179.2 million in 2022, then dropped by 2.90% to -$184.4 million in 2023, then slumped by 44.02% to -$265.5 million in 2024.